Literature DB >> 6088552

Regulation of transferrin receptors in human hematopoietic cell lines.

F Louache, U Testa, P Pelicci, P Thomopoulos, M Titeux, H Rochant.   

Abstract

Cells grown in the presence of ferric ammonium citrate or hemin exhibited a concentration and time-dependent decrease in 125I-transferrin (Trf) binding. In contrast, cells grown in the presence of protoporphyrin IX or picolinic acid (an iron chelator) exhibited a marked increase in Trf binding. The decrease or increase in binding activity observed under these different conditions of culture reflected, respectively, a reduction or increase in receptor number rather than an alteration in ligand receptor affinity. Growth of the cells in the presence of saturating concentrations of apotransferrin only induced a slight reduction in receptor number. Investigation of the Trf receptors' turnover and biosynthesis clearly showed that iron and hemin decreased the synthesis of Trf receptors without any modification of the receptor turnover; in contrast, protoporphyrin IX and picolinic acid markedly increased the synthesis of Trf receptors. Our results suggest that hemin, iron, and protoporphyrin IX may represent the main molecules involved in the regulation of Trf receptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088552

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Modulation of ferritin H-chain expression in Friend erythroleukemia cells: transcriptional and translational regulation by hemin.

Authors:  E M Coccia; V Profita; G Fiorucci; G Romeo; E Affabris; U Testa; M W Hentze; A Battistini
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

2.  Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron.

Authors:  R S Eisenstein; D Garcia-Mayol; W Pettingell; H N Munro
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

3.  Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.

Authors:  Takamasa Nishiuchi; Yuichi Okutani; Toshikazu Fujita; Kazuya Yoshida; Hiroaki Ohnishi; Reiji Haba
Journal:  Int J Hematol       Date:  2010-02-04       Impact factor: 2.490

4.  Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium.

Authors:  C R Chitambar; P A Seligman
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Chelation of transferrin iron by desferrioxamine in K562 cells. The partition of iron between ferrioxamine and ferritin.

Authors:  S Roberts; A Bomford
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

6.  The effect of lead on iron uptake from transferrin in human erythroleukemia (K562) cells.

Authors:  H Kohno; S Taketani; R Tokunaga
Journal:  Biometals       Date:  1993       Impact factor: 2.949

7.  Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.

Authors:  Minoru Kojima; Shinichiro Machida; Ai Sato; Mitsuki Miyamoto; Makiko Moriuchi; Yoshiaki Ohbayashi; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2013-10-26       Impact factor: 2.490

Review 8.  Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment.

Authors:  G Vreugdenhil; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

9.  The effect of desferrioxamine on transferrin receptors, the cell cycle and growth rates of human leukaemic cells.

Authors:  A Bomford; J Isaac; S Roberts; A Edwards; S Young; R Williams
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

10.  Expression of the haemopexin-transport system in cultured mouse hepatoma cells. Links between haemopexin and iron metabolism.

Authors:  A Smith; B E Ledford
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.